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Anaplastic large cell lymphoma (ALCL) is a rare, aggresive type of non-
Hodgkin lymphoma, more than half of which harbors an aberrant NPM-
ALK fusion protein. Both mTOR inhibitor everolimus and ALK 
inhibitor crizotinib have shown promising antitumor activity in ALK-
positive cancer cell lines. However, their combined effect has not yet 
been investigated. This study aimed to evaluate the combined effect of 
ii 
everolimus and crizotinib in ALK-positive ALCL cell lines, Karpas 299 
and SU-DHL-1. Western blot and flow cytometry were performed to 
elucidate the mechanism of combined effect as well. The results show 
that the combination of everolimus and crizotinib synergistically inhibit 
the growth of ALK-positive ALCL cells. Crizotinib attenuated ERK and 
AKT phosphorylation caused by everolimus. The combination treatment 
induced G1 cell-cycle arrest and increased apoptosis in ALK-positive 
ALCL cells. The synergistic effect of everolimus and crizotinib was also 
found in the non-small cell lung cancer cell line, NCI-H2228, that 
harbors a EML4-ALK fusion gene. In summary, everolimus combined 
with crizotinib synergistically inhibited the growth of ALK-positive 
ALCL cells by inhibiting ALK and mTOR phosphorylation and thus 
indirectly preventing aberrant ERK and AKT phosphorylation. Our 
results suggest that this combination could be used to improve the 
therapeutic outcome in patients with ALK-positive ALCL. 
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lymphoma, Anaplastic lymphoma kinase 
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INTRODUCTION 
Anaplastic large cell lymphoma (ALCL) is a rare, aggressive form of 
mature T-cell lymphoma, which comprises approximately 3% of adult 
non-Hodgkin lymphoma (NHL) and 10-15% of pediatric NHL (1). More 
than a half of ALCL harbors a nucleophosmin-anaplastic lymphoma 
kinase (NPM-ALK) fusion gene (2). The constitutively activated NPM-
ALK fusion protein consequently activates a number of signaling 
pathways such as Ras/ERK, PI3K/AKT, and JAK3/STAT3 (3-5). 
Although ALK fusion gene-positive (ALK-positive) ALCL patients have 
a better prognosis than those without (5-year overall survival of 70% vs. 
49%), those with relapsed or refractory disease generally had a poor 
prognosis (1, 2, 6). Thus, this genetic alteration could be a therapeutic 
target in this subset of patients. 
Crizotinib (also known as PF-02341066) is an ALK tyrosine kinase 
inhibitor that has an anti-proliferative activity in ALK-positive ALCL 
cell lines (7). In patients with lung adenocarcinoma harboring an EML4-
ALK fusion gene, crizotinib has shown substantial therapeutic efficacy 
(8, 9). However, in patients with ALK-positive ALCL, crizotinib has not 
yet been incorporated to standard clinical practice. 
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The mammalian target of rapamycin (mTOR) is a serine/threonine 
protein kinase which belongs to PI3K related kinases family. It is 
comprised of mTORC1 and mTORC2, and the activity of mTORC1 is 
regulated by PI3K/AKT and Ras/ERK pathway through TSC complex, 
which directly regulates mTOR activator Rheb by converting Rheb-GTP 
(active form) into Rheb-GDP (inactive form) (10, 11). The mTOR 
signaling pathway is frequently deregulated in many human cancers 
including anaplastic large cell lymphoma (12-14). Aberrant activated 
mTOR pathway has been detected in ALK-positive ALCL cell lines and 
up to 83% of ALK-positive ALCL tumors (12). Activation of this 
pathway promotes the driving protein synthesis, cap-dependent 
translation of mRNA, angiogenesis, invasion, metastasis, and 
proliferation of cancer cells (15, 16). Everolimus (also known as 
RAD001), an oral rapamycin analog, is an mTOR inhibitor which has 
been approved for the treatment of patients with advanced renal cell 
carcinoma or hormone receptor-positive breast cancer (17, 18) . 
Recently, in patients with diverse NHL subtypes, several clinical trials 
of everolimus have been performed and shown clinical activity (19, 20). 
However, the overall response rate of everolimus single treatment was 
only around 30% in these patients (21). 
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In this study, we aimed to evaluate the combined effect of everolimus 
and crizotinib in ALK-positive ALCL cell lines, Karpas 299 and SU-
DHL-1. The biologic mechanism of this combination treatment was also 
investigated. 
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MATERIALS AND METHODS 
1. Cell lines and culture
ALK-positive ALCL cell line Karpas 299 was obtained from Sigma-
Aldrich (St. Louis, MO, USA) and SU-DHL-1 from American Type 
Culture Collection (Manassas, VA, USA). EML4-ALK-positive lung 
adenocarcinoma cell line NCI-H2228 was obtained from American Type 
Culture Collection (Manassas, VA, USA). Cells were maintained in 
RPMI-1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum (GIBCO, Grand Island, NY, USA) and 1% 
penicillin/streptomycin (Lonza, Walkersville, MD, USA). All cells were 
incubated at 37℃ under an atmosphere of 5% CO2. 
2. Antibodies and reagents
Antibodies specific for phospho-mTOR (Ser2448), phospho-mTOR 
(Ser2481), phospho-AKT (Thr308), phospho-AKT (Ser473), phospho-
p70S6K (Thr389), and phospho-4E-BP1 (Thr37/46) were purchased 
from Cell Signaling Technology (Beverly, MA, USA). Anti-GAPDH 
antibody was purchased from Santa Cruz Biotechnology (Dallas, TX, 
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USA). Anti-PARP antibody was purchased from BD Pharmingen (San 
Jose, CA, USA). Everolimus and crizotinib were purchased from 
Selleckchem (Houston, TX, USA), dissolved in dimethyl sulfoxide and 
stored at -20℃. 
 
3. Cell viability assays 
Cell lines were seeded into 96-well plates and then incubated at 37℃ for 
72 hours. Cell viability was quantified using the Cell Counting Kit-8 
(CCK-8) (Dojindo Molecular Technologies, Kumamoto, Japan). CCK-8 
solution 10 μL was added to each well for 2 hours. The absorbance was 
measured at 450 nm in a microplate reader (Becton Dickinson Labware, 
Le Pont de Claix, France). All assays were performed 5 times. Data were 
normalized to the percentage of the control. 
 
4. Western blot analysis 
Karpas 299 cells were washed in ice-cold PBS, and then suspended in 
cell lysis buffer. The mixtures were placed on ice for 1 hour vortexed 
every 10 minutes. After centrifugation for 30 minutes at 13,000 rpm at 
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4℃ to remove cellular debris, the supernatant was collected. Protein 
quantification was performed by using Micro BCA™ Protein Assay Kit 
(Thermo Scientific, Rockford, IL, USA). The samples were boiled at 100℃ 
for 7 minutes, and 10-20 μg of each samples was loaded onto a 6%, 10%, 
12%, or 15% polyacrylamide gels. After electrophoresis, gels were 
electro-transferred onto polyvinylidene difluoride (PVDF) membranes 
(Millipore Corporation, Billerica MA, USA). After blocking with 5% 
skim milk and 5% BSA in Tris-buffered saline with Tween 20 (TBS-T) 
for 1 hour, the membranes were incubated with primary antibodies 
overnight at 4℃, followed by incubation with appropriate secondary 
antibodies for 1 hour the next day. A WEST-ZOL (plus) Western Blot 
Detection System (Gyeonggi-do, Korea) was used to develop the blot, 
detected by Medical X-Ray Film Blue from AGFA (Septestraat, Mortsel, 
Belgium). 
 
5. Cell cycle analysis 
The cell-cycle distribution was determined by propidium iodide (PI) 
staining. Karpas 299 cells were treated with everolimus and/or crizotinib. 
After 72 hours, cells were collected, washed with phosphate buffered 
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saline (PBS), fixed in ice-cold 70% ethanol for at least 2 days but less 
than 1 week. After stained with 42 μg/mL PI (Sigma-Aldrich), 140 
ng/mL RNase A (Invitrogen, Carlsbad, CA, USA), and 0.1% bovine 
serum albumin (BSA)/PBS, the cells were analyzed using the 
FACSCalibur cytometer (BD Biosciences, San Jose, CA, USA). Cells 
fell in sub-G1 area were considered apoptotic and were excluded from 
the whole percentage of the cell cycle analysis. 
 
6. Statistical analysis 
Experimental data were expressed as the mean ± standard error. The 
combination index (CI) was assessed by CalcuSyn software version 2.11 
(Biosoft, Cambridge, UK) using the median effect methods described by 
Ting-Chao Chou and Paul Talalay. A combination index of 1 indicates an 






1. Both everolimus and crizotinib inhibit the growth of human ALCL 
cells 
The cytotoxic effect of everolimus and crizotinib was evaluated in two 
ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. These cells 
were treated with increasing dose of everolimus (0.001-1 μM) or 
crizotinib (0.1-1 μM) for 72 hours and cell viability was assessed using 
the CCK-8 assay. Both everolimus and crizotinib potently inhibited the 
cell growth in a dose-dependent manner in the two cell lines (Figure 1). 
Calculated half maximal inhibitory concentration (IC50) values for 
everolimus were 3.76 nM in Karpas 299 and 2.69 nM in SU-DHL-1. 
Calculated IC50 values for crizotinib were 54.1 nM in Karpas 299 and 







Figure 1. Cytotoxic effect of everolimus and crizotinib on ALK-
positive ALCL cells. 
Human ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1, were 
treated with various concentrations of everolimus (A) or crizotinib (B) 
for 72 hours. Both everolimus and crizotinib potently inhibited the cell 
growth in a dose-dependent manner in the two cell lines. 
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2. Everolimus combined with crizotinib synergistically inhibits the 
growth of ALK-positive ALCL cells 
The ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1, were 
incubated with increasing concentrations of everolimus and/or crizotinib 
at a fixed ratio of 1:40. As shown in Figure 2, the combination of 
everolimus and crizotinib was more effective than each agent alone in 
inhibiting the growth of ALCL cell lines. All CI values were less than 1, 







Figure 2. Synergistic cytotoxicity of everolimus and crizotinib in 
ALK-positive ALCL cells. 
Karpas 299 cells (A) and SU-DHL-1 cells (B) were incubated with 
increasing concentrations of everolimus and/or crizotinib at a fixed ratio 
of 1:40. After 72 hours, the cell viability was estimated using the CCK-
8 assay and the CI values calculated using CalcuSyn software were 
shown in the graphs. All CI values were less than 1, indicating 




3. Everolimus and crizotinib have different effects on signaling 
pathways 
Western blot assays were performed to investigate the effect of 
everolimus and crizotinib on down-stream signaling pathways in Karpas 
299 cells. Previous studies showed that mTORC1 activity could be 
evaluated by examining the phosphorylation of Ser2448 on mTOR, 
while mTORC2 activity could be evaluated by the phosphorylation of 
Ser2481 (22) . Activity of mTORC1 was effectively decreased by an 
increased dose of everolimus, while the effect of crizotinib on mTORC1 
was relatively less potent. On the other hand, mTORC2 activity was 
potently inhibited by crizotinib, while everolimus could not effectively 
suppress mTORC2 activity (Figure 3). 
Phosphorylation of p70S6K was decreased by both everolimus and 
crizotinib treatment. In contrast, 4E-BP1 phosphorylation was increased 
by everolimus or crizotinib single treatments. Everolimus resulted in 







Figure 3. Effects of everolimus and crizotinib on signaling pathways. 
Karpas 299 cells were treated with 0 to 16 nM of everolimus (A) or with 
0 to 80 nM of crizotinib (B) for 24 hours. Everolimus mainly inhibited 
mTORC1 activity, while crizotinib inhibited mTORC2 activity. 
Phosphorylation of p70S6K was decreased, while 4E-BP1 
phosphorylation was increased in both cases. Everolimus increased ERK 





4. Crizotinib down-regulates everolimus-induced ERK and AKT 
phosphorylation and strengthens mTOR inhibition 
Combined effect of everolimus and crizotinib on signaling pathways was 
evaluated using western blot analysis. Karpas 299 cells were treated with 
4 nM everolimus and/or 80 nM crizotinib for 24 hours. The combination 
treatment suppressed ERK and AKT phosphorylation caused by 
everolimus in Karpas 299 cells (Figure 4). Combination treatment with 
everolimus and crizotinib also decreased phosphorylation of mTOR 
(Ser2448), mTOR (Ser2481), and p70S6K compared to single treatments. 
Decreased phosphorylation of mTOR (Ser2481) indicated that 
everolimus combined with crizotinib inhibited mTORC2 as well as 
mTORC1 activity. Although the combination of everolimus and 
crizotinib reduced activity of mTORC1, p70S6K, and mTORC2, 
phosphorylation of 4E-BP1, another substrate of mTORC1, was not 
decreased by the combination treatment compared to the control group. 
Considering the effect of single treatments in Figure 3, we had 
hypothesized that the combination treatment could increase 4E-BP1 
phosphorylation. However, the combination of everolimus and crizotinib 





Figure 4. Effective inhibition of signaling pathways using everolimus 
plus crizotinib combination treatment in Karpas 299 cells. 
Karpas 299 cells were treated with 4 nM everolimus and/or 80 nM 
crizotinib for 24 hours. The combination treatment more potently 
inhibited PI3K/AKT, Ras/ERK, and mTOR signaling pathways 





5. Combination of everolimus and crizotinib enhances apoptosis and 
induces cell cycle arrest 
To further evaluate the effect of crizotinib and everolimus combination 
on cell cycle and apoptosis, Karpas 299 cells were treated with 4nM 
everolimus and/or 80nM crizotinib for 72 hour, and then flow cytometry 
by PI staining was performed. As shown in Figure 5, the everolimus 
single treatment did not increase the fraction of cells in the sub-G1 region 
compared to the control (4.03% vs. 2.16%). In contrast, the fraction of 
cells in sub-G1 area was increased after crizotinib treatment compared 
to the control (11.88% vs. 2.16%). In addition, the combination of 
crizotinib and everolimus markedly increased the sub-G1 population 
(22.25%), which suggests increased apoptosis of the combination 
treatment. Crizotinib as a single agent significantly increased cell-cycle 
arrest in G0/G1 phase, while the effect of everolimus on cell cycle was 
not apparent. PARP cleavage was also increased after the combination 





Figure 5. Cell cycle arrest and apoptosis induction by everolimus 
plus crizotinib combination treatment in Karpas 299 cells. 
Karpas 299 cells were treated with 4 nM everolimus or/and 80 nM 
crizotinib for 72 hours and cell cycle distribution was assessed by flow 
cytometry (A). The cells were gated to sub-G1, G0/G1, S, and G2 phases 
according to their DNA contents (B). The combination of crizotinib and 
everolimus markedly increased the sub-G1 population compared to 
single treatments. In addition, crizotinib increased cell-cycle arrest in 




6. Everolimus combined with crizotinib synergistically inhibits the 
growth of ALK-positive lung adenocarcinoma cell line, NCI-H2228 
On the basis of the synergistic effect of everolimus and crizotinib 
observed in ALK-positive ALCL cell lines, it was also speculated that 
this combination treatment would be synergistic in ALK-positive lung 
cancer cells. ALK-positive lung cancer cell line NCI-H2228 was treated 
with everolimus and crizotinib at a fixed ratio of 1:80 for 72 hours, and 
then cell viability was determined by CCK-8 assays. As expected, 





Figure 6. Synergistic cytotoxicity of everolimus and crizotinib in 
ALK-positive lung cancer cell line NCI-H2228. 
NCI-H2228 cells were treated with everolimus and crizotinib at a fixed 
ratio of 1:80 for 72 hours. CI values calculated using CalcuSyn software 
were shown in the graphs. In all combinations, the CI values were less 
than 1, indicating synergistic cytotoxic effects of this combination 





The mTOR pathway is frequently deregulated in ALK-positive ALCL, 
indicating that mTOR could be a therapeutic target of ALK-positive 
ALCL (12, 23). However, the clinical efficacy of mTOR inhibitor 
monotherapy has not yet yield satisfactory results in patients with 
relapsed or refractory NHL (21), possibly due to the resistance 
mechanisms which activate several pro-surviving signaling pathways in 
response to mTOR inhibitors. 
Previous reports showed that mTORC1 inhibition using rapalogs leads 
to up-regulation of ERK and AKT by several different mechanisms (24-
27). The p70S6K, one of the major substrates of mTORC1, regulates the 
pathway via feedback mechanism by inhibiting PI3K through IRS1 
down-regulation. Thus, mTORC1 inhibition using rapalogs, which 
down-regulates p70S6K, leads to PI3K activation (24). The p70S6K also 
inhibits mTORC2 through phosphorylation of Rictor on Thr1135 (25). 
Therefore, p70S6K down-regulation by rapalogs allows mTORC2 
activity, leading to AKT phosphorylation on Ser473. In addition, mTOR 
inhibition increases PDGFR expression, leading to further AKT 
phosphorylation on Ser473 (26). ERK activation is also triggered by 
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mTORC1 inhibition through a p70S6K-IRS-Ras pathway in cancer 
patients as well as in vitro experiments and a preclinical model of 
prostate cancer (27). In our study, we observed that these resistance 
mechanisms to mTOR inhibitor were also found in ALK-positive ALCL 
cells (Figure 3). Recent studies revealed that simultaneous inhibition of 
PI3K/AKT and Ras/ERK pathways synergistically enhances the 
cytotoxic effect in a variety of malignancies, including lung and breast 
cancer, and rhabdomyosarcoma (27-29). 
In ALK-positive ALCL cells, the aberrant NPM-ALK fusion gene 
activates Ras/ERK, STATs, and PI3K/AKT signaling pathways. 
Crizotinib effectively inhibits phosphorylation of ALK, AKT, ERK, 
PLC-γ, and STAT3, both in vitro and in vivo (30). A previous report 
showed that two ALK-positive ALCL patients could achieve rapid 
complete remission after crizotinib treatment although they had 
previously relapsed after CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisone) chemotherapy (31). Another clinical study 
of crizotinib monotherapy in patients with relapsed or refractory ALK-
positive NHL exhibited the overall response rate of 91% (10 of 11) with 
2-year overall and progression-free survival rates of 72.7% and 63.7%, 
respectively (32). However, a substantial portion of patients eventually 
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experienced relapse or progression despite crizotinib treatment. 
Therefore, we hypothesized that, rather than as monotherapy, crizotinib 
can be used more effectively as a part of a combination therapy with 
other chemotherapeutic agents. In this paper, we demonstrate that 
crizotinib used in conjunction with everolimus can create synergistic 
cytotoxicity in ALK-positive ALCL cells by suppressing aberrant ERK 
and AKT phosphorylation induced by everolimus.  
As shown in Figure 7, the synergistic anti-proliferative effect of this 
novel combination suggested that ALK inhibition could help overcome 
everolimus resistance in ALK-positive ALCL cells by inhibiting down-
stream ERK and AKT signaling pathways. In addition, the effect of 
everolimus on mTORC1 and p70S6K down-regulation was strengthened 
by the addition of crizotinib. In particular, mTORC2, which is not a target 
of everolimus was also down-regulated by crizotinib. However, 4E-BP1 
phosphorylation was rather increased by everolimus or crizotinib single 
treatments. A previous study showed that rapamycin could induce 4E-
BP1 phosphorylation within 6 hours despite initial inhibition within 3 
hours (33). Crizotinib can also induce 4E-BP1 phosphorylation in ALK-
positive lung cancer cells although the precise mechanism remains 
unknown (34). Nevertheless, the combination of everolimus and 
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crizotinib appears to slightly decrease 4E-BP1 phosphorylation 
compared to single treatments in our study (Figure 4). Thus, it is 
speculated that everolimus and crizotinib may have antagonistic effect 
on 4E-BP1 phosphorylation. In addition, rapamycin-induced 4E-BP1 
phosphorylation could be abrogated by BKM120 (a PI3K inhibitor) or 
BEZ235 (a PI3K/mTOR dual kinase inhibitor) in lung cancer (35, 36) 
and bladder cancer (37) cells. Therefore, these novel drugs could be used 
to overcome the resistance of everolimus and crizotinib combination 
therapy. 
Everolimus and crizotinib have been known to induce G1 arrest in 
ALK-positive ALCL cells (30, 38). In accordance with these previous 
reports, crizotinib treatment showed G1 arrest in our study (Figure 5). 
However, G1 arrest was not apparent after everolimus treatment, 
possibly due to a much lower concentration of everolimus in this study 
compared to the previous study (4 nM vs. 10 nM) (38). The combination 
of everolimus and crizotinib resulted in G1 arrest, and the proportion of 
S and G2 population was decreased. Notably, the addition everolimus to 
crizotinib markedly increased Sub-G1 population, which reflects the 
proportion of apoptotic cells, compared to everolimus or crizotinib 
monotherapy. This phenomenon was in accordance with the increased 
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PARP cleavage after the combination treatment. 
Several ALK-fusion genes have been identified in a variety of cancers, 
such as lung adenocarcinoma, inflammatory myofibroblastic tumor, and 
renal cell carcinoma (39). Therefore, it is speculated that our finding 
could be applied to other cancers harboring ALK-fusion genes. We tested 
this hypothesis in ALK-positive lung adenocarcinoma cell line NCI-
H2228. As shown in Figure 6, the combination of everolimus and 
crizotinib showed synergistic cytotoxic effect in NCI-H2228 cells. This 
result suggest this combination might be an effective treatment in other 
cancers harboring ALK-fusion genes. 
In summary, the combination of everolimus and crizotinib 
synergistically inhibits the growth of ALK-positive ALCL cells. 
Crizotinib inhibited aberrant ERK and AKT phosphorylation induced by 
everolimus, and more effectively suppressed the activity of mTOR than 
everolimus monotherapy. Our study may provide an evidence of further 
preclinical studies and clinical trials using everolimus and crizotinib 
combination in ALK-positive ALCL. We suggest that this novel 












Figure 7. Schematic diagram of signaling pathways in ALK-positive 
ALCL cells. 
PI3K/AKT and Ras/ERK pathways are activated by NPM-ALK fusion 
protein in ALK-positive ALCL cells (A). Combination treatment of 
crizotinib and everolimus abrogates ERK and AKT up-regulation caused 
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역형성 대세포 림프종은 비호지킨림프종의 한 종류로서 
반수 이상의 환자에서 NPM-ALK 용합 유전자를 발현한다. 
ALK 억제제인 crizotinib 와 mTOR 억제제인 everolimus는 
NPM-ALK 융합 유전자를 가진 역형성 대세포 림프종 
세포주에 효과적인 항암 작용을 나타낼 것으로 기대된다. 
그러나, 아직 이 두가지 약제의 병합요법의 효과에 대한 
연구는 없다.  본 연구는 ALK 양성 역형성 대세포 림프종 
세포주인 Karpas 299, SU-DHL-1를 사용하여 everolimus 
와 crizotinib 의 병합요법의 효과를 평가하였다. 또한, 다양한 
실험을 통하여 본 병합요법의 작용 기전을 증명하였다. ALK 
양성 역형성 대세포 림프종 세포에서 everolimus와 
crizotinib 병합요법은 단일 요법에 비하여 세포 독성에대한 
상승작용(synergism)을 나타내었다. 그리고, crizotinib은 
everolimus에 의해 유도된 ERK와 AKT의 인산화를 
효과적으로 억제하였다. 또한, 본 병합요법은 ALK 양성 
역형성 대세포 림프종 세포에서 G1 세포주기정지 및 
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세포자멸사를 유도하였다. 본 병합요법에 의한 세포 독성 
상승작용는 EML4-ALK 융합 유전자를 가진 비소세포폐암 
세포주 NCI-H2228에서도 동일하게 관찰되었다. 요약하면, 
ALK 양성 역형성 대세포 림프종 세포에서 everolimus와 
crizotinib 병합요법은 ALK와 mTOR의 인산화를 동시에 
억제함으로써, everolimus에 의한 ERK와 AKT 활성화를 
차단하여 세포 독성 효과를 향상시켰다. 본 연구결과를 토대로 
향후 ALK 양성 역형성 대세포 림프종 환자의 치료 성적을 
향상시키는 데 도움을 줄 수 있을 것이다. 
 
주요어 : mTOR, Everolimus, Crizotinib, 역형성 대세포 림프종, 
Anaplastic lymphoma kinase 
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